Press release
Myocardial Infarction Treatment Landscape Analysis of 50+ Companies by DelveInsight | Leading Players - Mesoblast, AstraZeneca, and Others
Myocardial Infarction Treatment
To know more about Myocardial Infarction pipeline report offerings @ https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key takeaways from the Myocardial Infarction Pipeline Report
• DelveInsight's Myocardial Infarction pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Myocardial Infarction treatment.
• The leading Myocardial Infarction Companies such as CSL Behring, Idorsia, TRPHARM, ProSTEM, Ever Supreme Bio Technology Co., Ltd., Faraday Pharmaceuticals, Athera Biotechnologies, CeleCor Therapeutics, BIOCARDIA, INC., Beijing Northland Biotech, Olatec Therapeutics, and others are developing potential drug candidates to improve the Myocardial Infarction treatment scenario.
• The promising Myocardial Infarction therapies such as abciximab, BioMonitor, RPH-104 80 mg, Metoprolol- Toprol XL, AO Therapy (aqueous oxygen), Aliskiren, Vitalscan, and others.
• This segment of the Myocardial Infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Latest Breakthroughs and Developments in the Myocardial Infarction Treatment Landscape
• In June 2021, Idorsia Ltd (SIX: IDIA) declared the commencement of the Phase 3 registration study "SOS-AMI" to assess the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
• Currently, ProSTEM collaborates with Cipto Mangunkusumo Hospital and Medistra to conduct a clinical trial, "Allogeneic Stem Cell Therapy from Cord Tissue for Acute Myocardial Infarction."
• Umbilical cord mesenchymal stem cells (UMC01) by Ever Supreme Bio Technology Co., Ltd., for treating acute myocardial infarction (AMI) Phase the FDA approved I clinical trial in February 2018, and by TFDA in September of the same year for entering clinical trials; an investigation new drug research for treating stroke by stem cells via intravenous injection (IV) was also approved by the FDA for Phase I clinical-go in September 2018. Also, the TFDA Phase I clinical-go in March of 2020.
• In March 2021, Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing a potentially life-changing critical illness, announced that it had reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the protocol design and statistical analysis approach to be taken in Faraday's Phase 3 cardiovascular outcomes study evaluating FDY-5301 for the treatment of acute ST-segment elevation myocardial infarction (STEMI) in patients undergoing percutaneous intervention (PCI).
• Dapansutrile (Olatec Therapeutics) has been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models, including arthritis, asthma, acute myocardial infarction (AMI), contact dermatitis, multiple sclerosis, melanoma and breast cancers, spinal cord injury (SCI) and Alzheimer's disease.
• ATH3G10 is a first-in-class fully human antibody to target phosphorylcholine (PC), the head group of oxidized phospholipids (oxPLs), and an epitope on damaged or stressed cells. The candidate is initially being developed for patients with a large ST-elevation myocardial infarction (STEMI) who are at a high risk of heart failure.
Get an Myocardial Infarction Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Myocardial Infarction Overview
Myocardial Infarction (MI) is a term used for an event of heart attack which is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply. The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, sweating, nausea, vomiting, abnormal heart beating, anxiety, fatigue, weakness, stress, depression, and other factors. The immediate treatment of MI include, taking aspirin, which prevents blood from clotting, and nitro-glycerin to treat chest pain and oxygen. The heart attack can be prevented by taking an earlier action to lower those risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, drugs, monitoring of blood pressure every week, doing exercise every day, and loosing body weight. The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack.
Myocardial Infarction Emerging Drugs
• Dapagliflozin: AstraZeneca
• Remestemcel-L: Mesoblast
• And Many Others
Myocardial Infarction Pipeline Therapeutics Analysis
There are approx. 50+ key companies which are developing the therapies for Myocardial Infarction. The companies which have their Myocardial Infarction drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
For further information, refer to the detailed report @ Myocardial Infarction Emerging Therapies, click here: https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Myocardial Infarction Pipeline Report
• Coverage- Global
• Myocardial Infarction Companies- CSL Behring, Idorsia, TRPHARM, ProSTEM, Ever Supreme Bio Technology Co., Ltd., Faraday Pharmaceuticals, Athera Biotechnologies, CeleCor Therapeutics, BIOCARDIA, INC., Beijing Northland Biotech, Olatec Therapeutics, and others
• Myocardial Infarction Therapies- abciximab, BioMonitor, RPH-104 80 mg, Metoprolol- Toprol XL, AO Therapy (aqueous oxygen), Aliskiren, Vitalscan, and others
• Myocardial Infarction Therapeutic Assessment by Product Type
• Myocardial Infarction Therapeutic Assessment by Stage and Product Type
• Myocardial Infarction Therapeutic Assessment by Route of Administration
• Myocardial Infarction Therapeutic Assessment by Stage and Route of Administration
• Myocardial Infarction Therapeutic Assessment by Molecule Type
• Myocardial Infarction Therapeutic Assessment by Stage and Molecule Type
• Myocardial Infarction companies' collaborations, Licensing, Acquisition -Deal Value Trends
• Myocardial Infarction - Market Drivers and Barriers
Table of Content
• Introduction
• Executive Summary
• Myocardial Infarction: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Myocardial Infarction - DelveInsight's Analytical Perspective
• In-depth Commercial Assessment
• Myocardial Infarction Collaboration Deals
• Late Stage Products (Phase III)
• Dapagliflozin: AstraZeneca
• Mid Stage Products (Phase II)
• Remestemcel-L: Mesoblast
• Inactive Products
• Myocardial Infarction Key Companies
• Myocardial Infarction Key Products
• Myocardial Infarction- Unmet Needs
• Myocardial Infarction- Market Drivers and Barriers
• Myocardial Infarction- Future Perspectives and Conclusion
• Myocardial Infarction Analyst Views
• Myocardial Infarction Key Companies
• Appendix
Got Queries? Reach out for more information on the Myocardial Infarction Pipeline Report- https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myocardial Infarction Treatment Landscape Analysis of 50+ Companies by DelveInsight | Leading Players - Mesoblast, AstraZeneca, and Others here
News-ID: 2777233 • Views: …
More Releases from DelveInsight Business Research
Global Pharmaceutical Cartridges Market to grow at a CAGR of 7.39% to reach USD …
According to DelveInsight's analysis, The growth of the pharmaceutical cartridges market is largely fueled by the increasing prevalence of chronic diseases that require long-term and consistent medication use. Moreover, the rising trend of self-administered treatments and the growing preference for home-based healthcare are major contributors to market expansion. Technological advancements in drug delivery systems have further supported this growth by enhancing patient convenience, improving dosage precision, and promoting better treatment…
Global Nucleic Acid Amplification Testing Market to grow at a CAGR of 8.13% by 2 …
According to DelveInsight's analysis, The growing demand for Nucleic Acid Amplification Testing (NAAT) is primarily driven by the increasing prevalence of infectious and genetic diseases. Additionally, the rising incidence of cancer and the expanding R&D efforts by major industry players are further fueling market growth. Together, these factors are expected to support a strong upward trajectory for the NAAT market throughout the forecast period from 2025 to 2032.
DelveInsight's "Nucleic Acid…
Global Cardiac Mapping System Market to grow at a CAGR of 8.37% by 2032, Evaluat …
According to DelveInsight's analysis, The growing incidence of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, is driving the expansion of the cardiac mapping system market. These systems play a crucial role in the early detection and management of such conditions by providing real-time visualization of the heart's electrical activity, thereby reducing the risk of severe complications like stroke and heart failure. Moreover, the rising adoption of minimally invasive procedures,…
Global Graft Preparation System Market to grow at a CAGR of 4.17% to reach USD 3 …
According to DelveInsight's analysis, The demand for graft preparation systems is experiencing notable growth, primarily driven by the rising incidence of bone disorders and skin-related conditions. Moreover, the increasing number of surgical procedures worldwide, coupled with expanding R&D initiatives and strategic collaborations among leading market players, is further fueling market expansion. Together, these factors are expected to create a strong growth outlook for the graft preparation system market during the…
More Releases for Myocardial
Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Numb …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual…
Diabetes Epidemic Fuels Myocardial Ischemia Market Growth: An Emerging Driver Tr …
The Myocardial Ischemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Myocardial Ischemia Market?
The myocardial ischemia market has grown strongly. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a CAGR of 7.3%.…
Transforming the Myocardial Ischemia Market in 2025: Diabetes Epidemic Fuels Myo …
What Is the Expected Size and Growth Rate of the Myocardial Ischemia Market?
The market size for myocardial ischemia has demonstrated considerable growth over the last few years. There's a predicted growth from $0.79 billion in 2024 to $0.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historical period can be credited to the use of telemedicine and remote monitoring, the discovery…
Myocardial Infarction Treatment Market Growth and Insights 2024
"The Business Research Company recently released a comprehensive report on the Global Myocardial Infarction Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, Î' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026".
The Global market size of Myocardial Infarction Drugs Market was $XX…
Myocardial Ischemia - Pipeline Review, H1 2017 - Pharmaceutical Report
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm…
